Treatment
Quizartinib clinical trials
We’re tracking 9 recruiting studies that include Quizartinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Baltimore, MarylandAges 18 years+ - NCT03661307RecruitingPhase 1/Phase 2
Quizartinib, decitabine, and venetoclax for AML or high-risk MDS
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
Houston, TexasAges 18 years+ - NCT06740799RecruitingPhase 1
Quizartinib study for people with severe liver problems
This trial tests how the body processes quizartinib when the liver is severely impaired. It helps doctors understand if the dose needs to be adjusted for patients with liver issues.
Miami, FloridaAges 18–75 - NCT06262438RecruitingPhase 2
Quizartinib plus chemo for children with FLT3-ITD AML
This study adds a targeted drug called quizartinib to standard chemotherapy for children with a certain type of acute myeloid leukemia (AML) that has a FLT3-ITD gene change. The goal is to see if this combination is safe and effective for treating newly diagnosed patients.
Utrecht, UtrechtAges 1 month–18 years - NCT07478991RecruitingPhase 3
Azacitidine and venetoclax with or without quizartinib for older or unfit AML patients
This trial tests if adding quizartinib to the standard combination of azacitidine and venetoclax improves outcomes for older adults or those with health conditions who cannot have intensive chemotherapy for acute myeloid leukemia (AML). It may help patients with certain genetic changes in the FLT3 or NPM1 genes.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Phoenix, ArizonaAges 18 years+ - NCT06769490RecruitingPhase 1
Ziftomenib and Quizartinib combination for AML
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
Houston, TexasAges 18 years+ - NCT07548710RecruitingPhase 2
SA plus X for newly diagnosed AML
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+
What Quizartinib is being studied for
Conditions with recruiting Quizartinib studies.
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome
- High Risk Myelodysplastic Syndrome
- Recurrent High Risk Myelodysplastic Syndrome
- Refractory High Risk Myelodysplastic Syndrome
- AML With Mutated NPM1
- Acute Myeloid Leukemia, in Relapse
- NPM1 Mutation
Common questions
- Are there clinical trials studying Quizartinib?
- Yes. Clin2 currently lists 9 recruiting studies that include Quizartinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Quizartinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Quizartinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Quizartinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.